| COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study MC Garassino, JG Whisenant, LC Huang, A Trama, V Torri, F Agustoni, ... The Lancet Oncology 21 (7), 914-922, 2020 | 653 | 2020 |
| Gut microbiota and cancer: from pathogenesis to therapy S Vivarelli, R Salemi, S Candido, L Falzone, M Santagati, S Stefani, ... Cancers 11 (1), 38, 2019 | 483 | 2019 |
| Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme R Pallini, L Ricci-Vitiani, GL Banna, M Signore, D Lombardi, M Todaro, ... Clinical Cancer Research 14 (24), 8205-8212, 2008 | 423 | 2008 |
| Anticancer oral therapy: emerging related issues GL Banna, E Collovà, V Gebbia, H Lipari, P Giuffrida, S Cavallaro, ... Cancer treatment reviews 36 (8), 595-605, 2010 | 206 | 2010 |
| TMB or not TMB as a biomarker: That is the question A Addeo, A Friedlaender, GL Banna, GJ Weiss Critical reviews in oncology/hematology 163, 103374, 2021 | 143 | 2021 |
| Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the … CN Sternberg, Y Loriot, N James, E Choy, D Castellano, F Lopez-Rios, ... European urology 76 (1), 73-81, 2019 | 134 | 2019 |
| EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment A Friedlaender, V Subbiah, A Russo, GL Banna, U Malapelle, C Rolfo, ... Nature reviews Clinical oncology 19 (1), 51-69, 2022 | 131 | 2022 |
| Lactobacillus rhamnosus GG: An Overview to Explore the Rationale of Its Use in Cancer GL Banna, F Torino, F Marletta, M Santagati, R Salemi, E Cannarozzo, ... Frontiers in pharmacology 8, 603, 2017 | 121 | 2017 |
| How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere G Banna, A Curioni-Fontecedro, A Friedlaender, A Addeo ESMO open 4, e000765, 2019 | 116 | 2019 |
| First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status F Facchinetti, G Mazzaschi, F Barbieri, F Passiglia, F Mazzoni, R Berardi, ... European Journal of Cancer 130, 155-167, 2020 | 112 | 2020 |
| KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures A Friedlaender, A Drilon, GJ Weiss, GL Banna, A Addeo Cancer treatment reviews 85, 101978, 2020 | 106 | 2020 |
| Tumor mutation burden—from hopes to doubts A Addeo, GL Banna, GJ Weiss JAMA oncology 5 (7), 934-935, 2019 | 105 | 2019 |
| BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling MO Nicoletto, M Donach, A De Nicolo, G Artioli, G Banna, S Monfardini Cancer treatment reviews 27 (5), 295-304, 2001 | 104 | 2001 |
| Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: a systematic review and … A Addeo, GL Banna, G Metro, M Di Maio Frontiers in oncology 9, 264, 2019 | 99 | 2019 |
| Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab … A Cortellini, M Di Maio, O Nigro, A Leonetti, DL Cortinovis, JGJV Aerts, ... Journal for immunotherapy of cancer 9 (4), 2021 | 98 | 2021 |
| New emerging targets in cancer immunotherapy: the role of TIM3 A Friedlaender, A Addeo, G Banna ESMO open 4, e000497, 2019 | 89 | 2019 |
| Treatments of AIDS-related Kaposi's sarcoma SML Aversa, AM Cattelan, L Salvagno, G Crivellari, G Banna, ... Critical reviews in oncology/hematology 53 (3), 253-265, 2005 | 84 | 2005 |
| Immunotherapy in non-small cell lung cancer harbouring driver mutations A Addeo, A Passaro, U Malapelle, GL Banna, V Subbiah, A Friedlaender Cancer treatment reviews 96, 102179, 2021 | 83 | 2021 |
| Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression≥ 50%: a multicenter study with external validation A Cortellini, B Ricciuti, M Tiseo, E Bria, GL Banna, JGJV Aerts, F Barbieri, ... Journal for immunotherapy of cancer 8 (2), 2020 | 78 | 2020 |
| Next generation sequencing and genetic alterations in squamous cell lung carcinoma: where are we today? A Friedlaender, G Banna, U Malapelle, P Pisapia, A Addeo Frontiers in oncology 9, 166, 2019 | 78 | 2019 |
